The Priority Review

Tag

Deutenzalutamide

1 story

  1. Clinical trials

    Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer

    Hinova Pharmaceuticals Inc. has registered a Phase 3, randomized, double-blind, placebo-controlled study of Deutenzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with high-risk biochemical recurrence of prostate cancer. The study plans to enroll 1044 participants and is expected to start on October 31, 2026, with primary completion projected for December 31, 2029.